The tobacco industry giant, Altria Group, has experienced a stretch of dynamic stock performance in recent years. While shareholders have rejoiced moments of growth, the company's trajectory remain a topic of discussion. Factors affecting Altria Group's stock consist of governmental actions, shif

The landscape of diabetes management is continually evolving, bringing innovative therapies that offer improved efficacy and patient experience. Among these advancements, tirzepatide has emerged as a promising treatment option, demonstrating remarkable efficacy in clinical trials. As a dual GLP-1